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Abstract
This study was designed to investigate the cardioprotective effects of different concentrations of sevoflurane 
exposure on myocardial ischemia/reperfusion injury in in vivo rabbit hearts.
Rabbits were subjected to regional ischemia by 30 min of the left anterior descending artery (LAD) occlusion 
followed by 180 min of reperfusion under general anesthesia with ketamine and xylazine infusion.  The animals 
were randomly assigned to the following 5 treatment groups: a control group, a continuous infusion of 0.5% 
sevoflurane group, a 1.0% sevoflurane group, a 1.5% sevoflurane group and a 2.0% sevoflurane group. Sevoflurane 
infusion group animals received continuous exposure of sevoflurane from 5 minutes prior to ischemia up to the end 
of reperfusion.  At the end of the 180 min reperfusion period, risk area and infarct size were measured.
Heart Rate, mean arterial blood pressure, and rate pressure product revealed no significant difference among 
all the groups tested.  The risk area showed no significant differences among all the groups. Mean infarct size of 
the risk area was significantly less in 1.0% sevoflurane group and 1.5% sevoflurane group than a control group. 
The incidence and duration of arrhythmias during myocardial ischemia was no significant difference among all the 
groups.  The incidence of arrhythmias during reperfusion was significantly less in 1.5% and 2.0% sevoflurane group 
than a control group.  The duration of arrhythmias during reperfusion was significantly less in all the sevoflurane 
treatment groups compared with a control group.
These results suggest that 1.0% and 1.5% sevoflurane given before coronary artery occlusion has an infarct 
size limiting effect in the myocardium, and 1.5% and 2.0% sevoflurane has an antiarrhythmic effect during 
reperfusion in the rabbit heart.  It was suggested that the optimal concentration of sevoflurane to elicit the most 
potent cardioprotection is 1.5% in in vivo rabbit model.
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pre	ischemia ischemia	29min reperfusion	30min reperfusion	60min
HR
(beats/min)
Control 161.9±5.6 180.6±7.4 170.1±5.0 164.7±4.4
Group	0.5S 170.0±8.4 176.9±3.8 171.3±4.9 168.1±4.7
Group	1.0S 175.2±5.9 180.7±3.7 174.7±3.9 170.9±4.4
Group	1.5S 180.6±6.5 192.1±6.6 185.3±8.2 176.8±6.8
Group	2.0S 179.5±5.8 189.3±9.4 179.7±6.1 171.3±6.8
MAP
(mmHg)
Control 	 68.0±3.9 	 65.2±2.7 	 66.3±2.2 	 67.6±3.6
Group	0.5S 	 69.4±2.4 	 65.6±1.7 	 65.3±1.4 	 65.8±2.3
Group	1.0S 	 73.0±2.4 	 68.9±1.3 	 67.8±1.3 	 68.4±1.2
Group	1.5S 	 66.0±4.1 	 63.1±3.5 	 64.6±2.2 	 63.0±2.6
Group	2.0S 	 65.7±2.7 	 62.4±2.3 	 62.8±1.6 	 61.2±2.3
RPP
(mmHg/min)
Control 14114.1±879.7 14151.3±500.0 13844.8±472.3 13302.8±484.2
Group	0.5S 14439.9±840.0 13873.3±794.0 13730.4±826.4 13461.8±802.8
Group	1.0S 15456.1±544.4 15034.4±350.3 14820.3±447.9 14585.2±462.7
Group	1.5S 15996.9±1127.7 15683.1±1036.8 15211.8±936.6 15078.3±1000.3
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が発生したものはなかった。
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